This $3 Stock Could Cure Alzheimer's and Parkinson’s

$9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease. $9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease. [Energy and Capital logo] This $3 Stock Could Cure Alzheimer's and Parkinson’s [Jeff Siegel Photo] By [Jeff Siegel]( Written Sep 24, 2020 $9.1 billion… This is the combined value of the treatment market for Alzheimer’s disease and Parkinson’s disease: two diseases that wreaked havoc on my grandmother and great-grandmother. I’m not going to lie: Watching my loved ones suffer from these horrible diseases was not easy. And in fact, one of the reasons I’m often investing in the biotech space is because I want to be a part of any potential treatment for any variety of illnesses that still have no cure. The other reason, of course, is money. Lots of money. And that’s why I’m writing to you today. "Small Pill Could Save Millions of Lives" — Kevin O’Leary [kevin oleary shark tank]( Chronic diseases like alcoholism, opioid addiction, diabetes, and depression can be a death sentence for millions of sufferers. Regular treatments work only 30% of the time and can take years. Now the FDA has given the go-ahead to a small pill that wipes out these diseases with just one or two doses. And elite research institutions, like Johns Hopkins, Stanford, and Harvard, have replicated and confirmed the results. "Mr. Wonderful," Kevin O’Leary, has already invested millions. [Details here...]( $1 Billion up for Grabs I remember when my grandmother first started suffering from Parkinson’s. It wasn’t a pleasant time. You see, she was an artist. Her specialty was tropical wildlife scenes. Let’s just say there are a lot of bird paintings in my home. :) But when the Parkinson’s started kicking in, she couldn’t paint the way she used to. She struggled more and more to hold a paintbrush. Her vision suffered quite a bit, too. Eventually, her easel sat empty. It was heartbreaking. And what was so irritating was that there was nothing we could do. So when I recently read about a potential new cure for Parkinson’s, I was floored. Just think about how many people could have their lives back if such a thing really comes to fruition. And of course, as an investor, the wheels started turning too when I realized what the value of such a cure could be. Best Kept Secret of America’s Elite Exposed For decades, the country’s billionaires have been cashing in on a little-known income stream. Forbes calls it, "the biggest investment opportunity you’ve never heard of," and Business Insider describes it as, "one of the ‘very best’ income sources." But most Americans have no idea it even exists... until now. [Click here]( to learn how you can gain access to this income stream and start collecting $1,273, $3,127, or even $5,372 every single month. According to the Longevity Fund, a venture capital firm invests specifically in companies that are seeking cures for aging-related diseases, such as Parkinson’s. A single age-related indication could be worth a couple hundred billion dollars. That’s billion with a “B.” Now here’s the best part … This potential cure for Parkinson’s is being developed by a public company that [you can invest in right now](. Clinical trials are set to begin shortly, and if this thing proves to be effective, it will be a game-changer of epic proportions. Certainly for those suffering from Parkinson’s and other age-related chronic diseases, but also for investors who [get an early piece of this action](. You can read more about the science behind this potential cure [here](. And to learn more about the company, including its ticker symbol, [click here now](. To a new way of life and a new generation of wealth... [Jeff Siegel Signature] Jeff Siegel [[follow basic]@JeffSiegel on Twitter]( Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's [page](. The SEC Is Minting More Investors The SEC is changing its rules. Now there’s another way to become accredited. Forget your net worth. Now, you can qualify with “established, clear measures of financial sophistication,” according to Chairman Clayton. The possibility of more people in the private market is astounding, but that’ll cut right into most profit opportunities. Don’t forget that because of HR 3606 almost any American can now buy into high-growth startups well before they hit the market... Fat slices of wealth are up for grabs, but now there are so many reaching hands. That’s where our in-house private placement insider, Jason Williams, comes in... A former Morgan Stanley banker, he has the contacts and knows exactly how you can make millions by getting into these opportunities. [Click here now to see his presentation.]( Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Oil Price Forecast 2021: Oil's Fundamental Reckoning]( [Lumber, the Triple Q's and COVID Projects]( [Tap-&-Go Investing in 2021 and Beyond]( [Viral Pandemics Are the New Terrorists]( [The Four Must-Own Stocks of the Cashless Revolution]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Energy and Capital](, Copyright © 2020, [Angel Publishing LLC](. All rights reserved. 3 E Read Street, Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Energy and Capital]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. ---------------------------------------------------------------